Yayın:
Biosilver nanoparticle interface offers improved cell viability

dc.contributor.authorVanOosten, Sarah Kay
dc.contributor.authorYuca, Esra
dc.contributor.authorKaraca, Banu Taktak
dc.contributor.authorBoone, Kyle
dc.contributor.authorSnead, Malcolm L.
dc.contributor.authorSpencer, Paulette
dc.contributor.authorTamerler, Candan
dc.date.accessioned2026-06-27T13:55:48Z
dc.date.issued2016
dc.description.abstractSilver nanoparticles (AgNP) are promising candidates for fighting drug-resistant infections because of their intrinsic antimicrobial effect. The design of high-yield antimicrobial molecules may inadvertently cause variation in host cells' biological responses. While many factors affect AgNPs' efficacy, their surface is exposed to the biological environment and thus plays a critical role in both the preservation of antimicrobial efficacy against pathogens and the modulation of host cells cytotoxicity. This work investigated an engineered biomimetic interface approach to controlling AgNP surface properties to provide them a competitive advantage in a biological environment. Here, a fusion protein featuring a silver-binding peptide (AgBP) domain was engineered to enable self-assembly and track assembly by a green fluorescent protein (GFP) reporter. Following AgNP functionalisation with GFP-AgBP, their antimicrobial and cytotoxic properties were evaluated. GFP-AgBP binding affinity to AgNPs was evaluated using localized surface plasmon resonance sensing. The GFP-AgBP biomimetic interface on AgNPs' surfaces provided sustained antibacterial efficacy at low concentrations based on bacterial growth inhibition assays. Viability and cytotoxicity measurements in fibroblast cells exposed to GFP-AgBP protein-functionalised AgNPs showed significant improvement compared to controls. Biointerface engineering offers promise towards tailoring AgNP antimicrobial efficacy while addressing safety concerns to maintain optimum cellular interactions.en
dc.description.sponsorshipNational Institutes of Health (NIH)-National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR062249-03]
dc.description.sponsorshipNIH-National Institute of Dental and Craniofacial Research [R01DE025476-01]
dc.description.sponsorshipNew Faculty General Research Fund (NFGRF) through the University of Kansas
dc.description.sponsorshipNational Institute of Dental and Craniofacial Research [R01DE025476] Funding Source: NIH RePORTER
dc.description.urihttps://doi.org/10.1680/jsuin.16.00010
dc.identifier.doi10.1680/jsuin.16.00010
dc.identifier.eissn2050-6260
dc.identifier.endpage132
dc.identifier.issn2050-6252
dc.identifier.issue3
dc.identifier.pubmed29057075
dc.identifier.startpage121
dc.identifier.urihttps://hdl.handle.net/20.500.14981/55834
dc.identifier.volume4
dc.identifier.wos000388885500003
dc.language.isoeng
dc.publisherICE PUBLISHING
dc.relation.ispartofSURFACE INNOVATIONS
dc.subjectanti-microbial
dc.subjectbiointerface
dc.subjectnanoparticles
dc.subjectQUATERNARY AMMONIUM-COMPOUNDS
dc.subjectSILVER NANOPARTICLES
dc.subjectANTIMICROBIAL POLYMERS
dc.subjectANTIBACTERIAL ACTIVITY
dc.subjectCHIMERIC PEPTIDES
dc.subjectCYTOTOXICITY
dc.subjectPROTEIN
dc.subjectAGENTS
dc.subjectTOXICITY
dc.subjectRESISTANCE
dc.subjectChemistry
dc.subjectMaterials Science
dc.titleBiosilver nanoparticle interface offers improved cell viability
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar